TD Cowen raised the firm’s price target on AstraZeneca (AZN) to $105 from $95 and keeps a Buy rating on the shares. The firm said the company has promising new products and pipeline and participates in many large, high-growth markets. Numerous events are upcoming for investors to assess progress. EPS growth appears to be above industry average, with upside possible.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo dose first patient in DESTINY-Ovarian01 trial
- AstraZeneca price target raised to 16,000 GBp from 14,000 GBp at JPMorgan
- JPMorgan ups AstraZeneca target, adds to Analyst Focus List
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform